Bli medlem
Bli medlem

Du är här

2016-05-12

Hansa Medical: Resolutions adopted at the annual general meeting of Hansa Medical AB (publ)

N.B. the English version below is an office translation. In case of
any discrepancy between the Swedish and the English version, the
Swedish version shall prevail.

The following resolutions, among others, were adopted by the annual
general meeting of Hansa Medical AB (publ) held on 11 May 2016.

Dividend
The annual general meeting resolved that no dividend will be paid for
the financial year 2015.

Discharge from liability
The annual general meeting granted the directors and CEO discharge
from liability in respect of the 2015 financial year.

Board of directors and auditor
The annual general meeting resolved to re-elect Birgit Stattin
Norinder, Stina Gestrelius, Hans Schikan and Per Olof Wallström as
Board members and to elect Ulf Wiinberg and Angelica Loskog as Board
members. Ulf Wiinberg was elected chairman of the Board. The annual
general meeting resolved to re-elect KPMG AB in Malmö as the
company's auditor.

Angelica Loskog, born 1973, is Doctor of Philosophy (Faculty of
Medicine) and adjunct professor at the Department of Immunology,
Genetics and Pathology at Uppsala University. Loskog is scientific
advisor to Nexttobe AB, CEO of Lokon Pharma AB, as well as chairman
of Vivolux AB and Repos Pharma AB. She is independent of the company
and its management but not to major shareholders of Hansa Medical.
She owns no shares in the company.

Ulf Wiinberg, born 1958, has extensive experience in the
pharmaceutical industry. Previously CEO of H. Lundbeck A/S and
Wiinberg has held senior positions at Wyeth. Wiinberg is a Board
member of Alfa Laval AB and Nestle Health and Science and chairman of
the Board of Avillion, and is nominated for the Board of directors of
the Belgian pharmaceutical company UCB. He is independent of the
company and its senior management and independent of major
shareholders of Hansa Medical. He owns 75 000 shares in the company.

The annual general meeting resolved on remuneration to the Board as
follows. Remuneration to the Board members: SEK 500,000 to the
Chairman of the Board and SEK 110,000 each to the other Board Members
except for Angelica Loskog. Remuneration to the Board committees: SEK
40,000 to the chairman and SEK 30,000 each to the other Board Members
in the audit committee, SEK 40,000 to the chairman and SEK 25,000
each to the other Board Members in the Remuneration Committee and SEK
25,000 each to the Board Members in the Scientific Committee. A Board
Member may, if it is in accordance with current tax legislation and
provided that it is cost neutral for the company, be given the
possibility to invoice the remuneration from his own company,
provided that the company is registered for corporate tax (sw.
F-skatt). Social contributions fees and VAT will be added to such
remuneration invoiced by Board Member within a business operation.
The annual general meeting furthermore resolved on remuneration to
the auditor according to an authorized account.

In addition, the annual general meeting also adopted resolutions
regarding instructions for the nomination committee as well as
guidelines regarding compensation to senior executives.

The information in this communiqué is disclosed pursuant to the
Securities Markets Act or the Financial Instruments Trading Act. The
information was released for public disclosure on May 12, 2016, at
08.00 CET.

For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: 46 70-633 30 42
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focusing on novel
immunomodulatory enzymes. The lead project IdeS is an
antibody-degrading enzyme in clinical development, with potential use
in transplantation and rare autoimmune diseases. Additional projects
focus on development of new antibody modulating enzymes, as well as
HBP, a diagnostic biomarker for prediction of severe sepsis at
emergency departments that is already introduced on the market. The
company is based in Lund, Sweden. Hansa Medical's share (ticker:
HMED) is listed on Nasdaq Stockholm.

-----------------------------------------------------------
http://news.cision.com/hansa-medical/r/resolutions-adopted-at-the-annual...
http://mb.cision.com/Main/1219/2007503/514649.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.